4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage genetic medicines company, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's management will engage in a fireside chat and be available for one-on-one meetings during the event.
Key details of the presentation:
- Date: Thursday, August 15, 2024
- Time: 12:00 p.m. ET
A webcast of the presentation will be available, and an archived version will be accessible for up to one year on the company's investor relations website. This event provides an opportunity for 4DMT to showcase its progress in developing genetic medicines for large market diseases, particularly in the field of ophthalmology.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FDMT gained 1.35%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Members of the management team will also be available for one-on-one meetings.
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
| Presentation Date: | Thursday, August 15, 2024 |
| Presentation Time: | 12:00 p.m. ET |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine Smith
Inizio Evoke Comms
Katherine.Smith@inizioevoke.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When is 4D Molecular Therapeutics (FDMT) presenting at the H.C. Wainwright Ophthalmology Conference?
Will there be a webcast of FDMT's presentation at the H.C. Wainwright conference?
What type of event is FDMT participating in at the H.C. Wainwright conference?
What is the focus of 4D Molecular Therapeutics (FDMT)?
